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Abstract Apoptosis specific proteins (ASP) are expressed in the
cytoplasm of cultured mammalian cells of various lineages
following induction of apoptosis. The cDNA encoding ASP has
been cloned from a human expression library and has significant
homology to the Saccharomyces cerevisiae APG5 gene which is
essential for yeast autophagy. The ASP gene, known as hAPG5,
can be transcribed to give mRNAs of 3.3 kbp, 2.5 kbp and 1.8
kbp which are present at comparable levels in viable and
apoptotic cells, demonstrating that protein expression must be
regulated at the translational level. These data indicate a possible
relationship between apoptosis and autophagy and suggest
evolutionary conservation in mammalian apoptosis of a degra-
dative process present in yeast.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Apoptosis is an active form of cell death and is of funda-
mental importance in tissue development and homeostasis [1^
3]. The ability to initiate apoptosis appears to be a property of
virtually all metazoan cells, with the cell death mechanism
being highly conserved throughout evolution [4]. A closely
related series of well-characterised activators, inhibitors and
e¡ectors are responsible for the regulation of the process in
most cell types [5^7]. For example functionally and structur-
ally homologous cell survival factors occur in mammals (en-
coded by bcl-2), Caenorhabditis elegans (encoded by the ced-9
gene) [8] and viruses (for example adenovirus E1B and EBV
BHRF1 gene [9,10]). Similarly the C. elegans ced-3 gene en-
codes a protein related to the caspase family of vertebrate
cysteine proteases [11]. These proteins appear to play impor-
tant roles in the apoptotic process under certain, but not
necessarily all, circumstances (see for example [6,7]).
Much less well-understood, however, are the changes in
protein expression or structure which may be associated
with morphological changes which are common to apoptotic
cells. It has been known for some time that the degradation of
nuclear lamins precedes DNA fragmentation in the nucleus of
apoptotic cells [12]. In addition, a number of cellular enzymes
and regulators such as FAK [13], PARP [14] and Rb [15] are
known to be degraded during apoptosis. These events, how-
ever, are probably more closely linked to the action of the
caspases than to morphological change. Perhaps more surpris-
ingly we have recently demonstrated a dramatic increase in
level of expression, in apoptotic cells, of a 45 kDa protein
which appears to be associated with the cytoskeleton [16].
This protein was ¢rst observed in Burkitt’s lymphoma cells
and transformed retinoblasts [16] but has since been detected
in all mammalian cells examined following induction of apop-
tosis. Here we report the isolation and characterisation of the
cDNA encoding this apoptosis speci¢c protein (which we have
termed ASP). DNA sequencing demonstrates the human
cDNA to be novel but to be homologous to the yeast
APG5 gene which is necessary for autophagy. We conclude
that apoptosis and autophagy may be related processes em-
ploying some of the same proteins and/or biochemical mech-
anisms.
2. Materials and methods
2.1. Cloning a cDNA encoding an apoptosis speci¢c protein
Previously apoptosis speci¢c proteins have been identi¢ed by cross-
reactivity of a c-Jun antibody (Ab2, Oncogene Science). Using this
antibody a human foetal liver ZAP Express EcoRI/XhoI library was
screened (Stratagene). The ExAssist Helper Phage (Stratagene) was
then used to generate phagemids from positive bacteriophage. This
generated the 3P end of the cDNA. The 5P sequence was generated
using a human foetal brain RACE library (Clontech). The gene spe-
ci¢c primers used were: 1, 5P-CTGTGATGTTCCAAGGAAGAG-
CTG-3P and 2, 5P-GATAATGCCATTTCAGTGGTGTGCCTTC-3P.
A 373A ABI Gene Sequencer and Prism FS Dye terminator kit were
used for sequencing.
2.2. Southern blotting
The commercially available ¢lter used consisted of 4 Wg of genomic
DNA per lane extracted from nine eukaryotic species (Clontech). The
probe used for hybridisation was a 32P-labelled 1 kbp PCR product
from the hAPG5 sequence. Hybridisation was at 65‡C for approxi-
mately 16 h using the bu¡er conditions suggested by the manufac-
turer. Signals were then visualised using Kodak XAR-2 ¢lm at 370‡C
over a period of 2^3 days.
2.3. Northern blotting
The Northern blot contained 2 Wg of poly(A) mRNA extracted
from the human tissues speci¢ed separated on a formaldehyde agarose
gel (Clontech). The ¢lter was hybridised with a 32P-labelled hAPG5
speci¢c probe for approximately 16 h at 42‡C. The prehybridisation
and hybridisation bu¡er used was 5USSPE, 10UDenhardt’s, 100 Wg/
ml salmon sperm and 50% de-ionised formamide. Signals were visual-
ised as before over a period of 4^5 days.
2.4. Western blotting
Cells were rinsed with cold saline, harvested by centrifugation and
solubilised in 9 M urea, 50 mM Tris-HCl pH 7.3, 0.15 M L-mercap-
toethanol. Aliquots, containing 50 Wg of protein, were fractionated by
SDS-PAGE and subjected to Western blotting using an antibody
against human c-Jun (Oncogene Science Ab2) at a dilution of 1 in
200. Antigens were visualised using ECL (Amersham).
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2.5. DNA transfections
Transient transfections were carried out using the LipoTAXI (Stra-
tagene) and the protocol supplied by the manufacturer. 20 Wg of DNA
was used per transfection.
3. Results
Apoptosis speci¢c proteins were originally demonstrated
[16] in apoptosing human and rodent cell lines by cross-reac-
tivity of an antibody (Oncogene Science) raised against a pep-
tide equivalent to part of the human c-Jun sequence (amino
acids 73^87, TPTPTQFLCPKNVTD). In addition, it has re-
cently been shown to be expressed in human tissues, such as
tonsil, liver and pancreas undergoing apoptosis (our unpub-
lished data).
These initial studies indicating the widespread distribution
of ASP in apoptotic cells of diverse origin suggested that the
protein might play an important role in the apoptotic process,
possibly within the modi¢ed cytoskeleton [16]. If this were the
case, it might be expected that ASP expression would be a
relatively ‘late’ event in cells undergoing apoptosis. To inves-
tigate this further, BOC-ASP-CH2F OMe (100 WM), a caspase
inhibitor, was added to Cos-1 cells at the same time as they
were induced to apoptose with cisplatin (50 Wg/ml). It can be
seen from the Western blot shown in Fig. 1 that no ASP was
expressed after the addition of the caspase inhibitor together
with cisplatin, whereas the DNA damaging agent alone
caused ASP expression after 10 h and caused the morpholog-
ical changes normally associated with apoptosis (data not
shown).
Thus, it can be seen that ASP is expressed only after events
attributable to caspase activity. In an attempt to obtain fur-
ther clues to its function the gene encoding ASP was cloned
by screening human cDNA libraries with the antibody against
c-Jun. Initially a human foetal liver ZAP Express EcoRI/XhoI
library was screened. ExAssist Helper phage were used to
generate phagemids from positive bacteriophage. By this ap-
proach the 3P end of the ASP cDNA was isolated. The re-
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Fig. 1. The e¡ect of a caspase inhibitor on ASP expression. Cos-1
cells were incubated with cisplatin (50 Wg/ml) either in the presence
or in the absence of BOC-ASP-CH2F OMe (100 WM). At the times
indicated, cells were harvested and aliquots (containing 50 Wg pro-
tein) subjected to PAGE and Western blotting using an antibody to
c-Jun. The positive control used was apoptotic rodent cells.
Fig. 2. Primary structure of ASP and sequence homology to APG5 from S. cerevisiae. The predicted amino acid sequence of human ASP is
shown. The start site 3P end of the original cDNA is at amino acid 5. APG5 was translated from ORF YPL149W on S. cerevisiae chromosome
XVI. A potential glycosylation site was identi¢ed at N99, casein kinase II phosporylation sites at T29, S106, T192, T214, S225 and S259, pro-
tein kinase C phosphorylation sites at T28, T49 and T194 and a tyrosine kinase site at Y36. The amino acid sequence of ASP was aligned
with APG5 using the Genetics Computer Group GAP program. M indicates an identical match; : amino acids of strong similarity; W amino
acids of weak similarity. T indicates a gap introduced into the sequence to give maximum homology. A possible match to the c-Jun peptide
used to raise the antibody used in this work is underlined. Homology analyses and motif searches were performed with the Genetics Computer
Group package (Version 8, Madison Wisconsin) or BLAST [19] with the National Centre for Biotechnology Information BLAST network serv-
ice using the non-redundant protein database. Information on S. cerevisiae ORFs was obtained from the S. cerevisiae Genome Database at
Stanford University via the worldwide web. The hAPG5 sequence is available from EMBL/GenBank/DDBJ under accession number Y711588.
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maining 5P sequence was generated using a human foetal
brain RACE library. The DNA isolated was 3.3 kbp in length
with an open reading frame of 828 bp, the remaining nucleo-
tide sequence containing 3P and 5P untranslated regions. The
encoded protein comprises 276 amino acids with a preponder-
ance of acidic residues. A potential glycosylation site is
present at amino acid N99. In addition potential casein kinase
II, protein kinase C and tyrosine kinase sites are present as
indicated in the legend to Fig. 2.
A data base search revealed a signi¢cant homology between
the amino acid sequence of ASP and the predicted product of
the Saccharomyces cerevisiae APG5 gene ^ a member of a
large family of genes involved in yeast autophagy [17]. The
APG5 product is believed to be necessary for the correct
processing of autophagic bodies under conditions of nitrogen
starvation [17,18] (Fig. 2). 26% of the amino acids were iden-
tical in ASP and the APG5 product with 46% considered to be
FEBS 20033 3-4-98
Fig. 3. Distribution of ASP. A: Distribution of the hAPG5 gene in
eukaryotes. A Southern blot containing 4 Wg of genomic DNA per
track (Clontech) was probed with 32P-labelled hAPG5 cDNA for 16
h at 65‡C using the conditions recommended by the manufacturers.
After washing the Southern blot was exposed to Kodak XAR-2 ¢lm
at 370‡C. Species from which genomic DNA was prepared are
shown over each lane. B: Level of hAPG5 mRNA in human tissues.
Northern blot containing 2 Wg of poly(A) mRNA per track (Clon-
tech) was probed with 32P-labelled ASP cDNA for 16 h at 42‡C.
Blots were hybridised and washed as speci¢ed by the manufacturer.
The Northern blot was exposed to Kodak XAR-2 ¢lm at 370‡C.
Human tissues from which mRNA was prepared are indicated over
the appropriate lane. C: hAPG5 mRNA in apoptosing cells. Cos-1
cells were incubated in the presence of 50 Wg/ml cisplatin. At the
time points indicated total RNA was extracted from the cells using
RNAzol B and the protocol recommended by the manufacturer.
5 Wg of the RNA obtained was used to produce cDNA using the
Superscript kit from Gibco. A PCR was then performed on 2 Wl of
the resultant cDNA using the following primers: 5P-3P AGC TGG
ATC CAT GAC AGA TGA CAA AGA TGT GCT TCG AGA
TGT GTG G and 3P-5P GGG TGA CAT GCT CTG GGA TCC
CCC ATT TAA GGA TG. In each case 24 cycles were conducted
to ensure the reactions remained in the exponential phase. Relative
levels of gapdh were quanti¢ed using a densitometer and were
found to be constant, whilst the relative quantities of hAPG5 cDNA
were determined by hybridisation with a hAPG5 cDNA speci¢c
probe. The positive control shown (+) was obtained using hAPG5
plasmid DNA in the PCR. D: Data from RT-PCRs. The experi-
ment described in C was performed four times. Blots similar to that
shown in C were subjected to densitometric scanning. Data obtained
for each time point were normalised to the level of hAPG5 cDNA
seen for the untreated, viable cells. These data are displayed in the
histogram shown, n = 4. E: ASP expression in apoptotic Cos-1 cells.
Cos-1 cells were treated with cisplatin (50 Wg/ml) as in C. Cells were
harvested at the times indicated and samples subjected to Western
blotting using the c-Jun (Ab2) antibody. All lanes contain a total of
50 Wg of protein.
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similar. The homology was reasonably well distributed
throughout the sequence which suggests that the similarity is
not attributable to the conservation of a common domain or
motif.
Southern blotting has established the presence of the
hAPG5 gene in a number of di¡erent mammalian species as
well as in birds (Fig. 3A), consistent with our previous West-
ern blotting data using the c-Jun antibody ([16]; our unpub-
lished data) which suggested that the protein was widely dis-
tributed. A number of human tissues were examined for the
presence of mRNA transcribed from the hAPG5 gene It can
be seen (Fig. 3B) that the message is present in all tissues
examined in approximately equal abundance. Two major
transcripts of 3.3 kbp and 1.8 kbp were seen and a minor
one of 2.5 kbp. It is presumed that these products arise
through di¡erential splicing although homology with a related
gene cannot be ruled out.
It has previously been shown that expression of ASP in-
creases dramatically as cells undergo apoptosis [16]. To deter-
mine whether this increase was regulated transcriptionally or
translationally the level of mRNA in Cos-1 cells induced to
apoptose by the addition of cisplatin (50 Wg/ml for a period of
16 h) was examined using RT-PCR. A representative blot is
shown in Fig. 3C. It can be seen that, whilst the overall level
of hAPG5 mRNA remains reasonably constant, some varia-
tions are apparent. To determine whether the detected £uctu-
ations in level of mRNA are signi¢cant, four separate experi-
ments were carried out. After densitometric scanning of the
blots the intensity of the band for each time point was nor-
malised to that obtained for the viable, untreated cells. The
data from the four blots are presented in graphical form in
Fig. 3D. We conclude that there is no change in hAPG5
mRNA following the addition of cisplatin and consequent
apoptosis (con¢rmed by acridine orange staining, data not
shown). However, Western blotting of similarly treated sam-
ples showed an appreciable increase in ASP expression (Fig.
3E).
The hAPG5 open reading frame encodes a protein of 276
amino acids with a theoretical molecular weight of 32.4 kDa
which is appreciably smaller than the major 45 kDa ASP band
observed during Western blotting of apoptotic cells. When the
ASP cDNA was expressed in Escherichia coli the major prod-
uct detected was of the predicted molecular weight 32 kDa.
However, when hAPG5 cDNA was transiently transfected
into Cos-1 cells two bands were detected by Western blotting
^ a protein of 32 kDa similar to that seen after expression in
E. coli as well as a 45 kDa protein similar to that seen in
apoptotic cells (Fig. 4). We have concluded that a post-trans-
lational modi¢cation is responsible for the large discrepancy
in molecular weights between ASP expressed in bacteria and
mammalian cells.
4. Discussion
It has previously been shown that the expression of a pro-
tein of 45 kDa molecular weight is dramatically increased in a
variety of cell lines in response to stimuli which induce apop-
tosis [16]. Here we present evidence to show that this protein
is encoded by a novel gene with an open reading frame of 828
bp which is homologous to a yeast gene required for autoph-
agy [18]. Autophagy has been shown to be a general response
of mammalian cells to serum deprivation and usually involves
the sequestration of intracellular organelles and cytoplasm in
autophagosomes which subsequently fuse with lysosomes (see
for example [21,22]). A comparable process occurs in yeast
[23]. Thus it appears that whilst autophagy and apoptosis
have distinct features, similar proteins are involved in each
process. The functions of ASP (hAPG5) and APG5 are not
well understood, but on the basis of our previous studies we
consider that the proteins may be involved in the maintenance
of the integrity of apoptotic and autophagic bodies. Whilst
the similarities in the amino acid sequences of ASP and APG5
suggest a functional homology, we have no evidence to sup-
port this at present. The complementation of yeast with a
‘knocked out’ APG5 phenotype with the hAPG5 cDNA will
be required to resolve this point unequivocally. It is worth
noting, however, that a number of proteins with proven func-
tional conservation in yeast and humans have a comparable
amino acid identity to that seen for APG5 and ASP. For
example, the identity between Schizosaccharomyces pombe
and human co¢llin is 35.1%, elongation factor 1Q 36.9% and
rad 54 and ERC6 33.5%.
The observation that hAPG5 mRNA is present at similar
levels in viable and apoptotic cells strongly suggests that in-
creases in ASP expression are largely, perhaps entirely, attrib-
utable to increases in translation of pre-existing mRNA. This
conclusion is consistent with our inability to detect hAPG5
mRNA in a number of di¡erent cell types by in situ hybrid-
isation (data not shown). Interestingly no increase in APG5
mRNA was seen in yeast undergoing autophagy [18] indicat-
ing that regulation of expression of ASP and APG5 may be
by a similar mechanism. It seems likely that the ASP observed
after transient transfection of the cDNA (Fig. 4) is attribut-
able to the temporary very high levels of message such that in
this case, unusually, ASP expression can occur in the absence
of the remainder of the apoptotic process.
The introduction of ASP into viable Cos-1 cells (Fig. 4)
appeared to have no e¡ect on cellular morphology and did
not induce apoptosis. This is consistent with data presented in
Fig. 1 which demonstrated that ASP expression was a rela-
tively late event in the apoptotic process occurring down-
stream of caspase activity.
The discrepancy between the predicted and observed mo-
lecular weights for ASP is not simply explained. However, it
has been shown that enzymes present in eukaryotic, but not
prokaryotic, cells are necessary for the conversion. Further-
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Fig. 4. Transient transfection of Cos-1 cells with pSG5/hAPG5. Cos-
1 cells were transfected using the LipoTAXI reagent [20]. 48 h after
transfection the cells were harvested and the proteins extracted. 50
Wg of each sample was electrophoresed on a SDS gel. A Western
blot was carried out using the c-Jun (Ab2) antibody. Cells were
transfected with either pSG5/hAPG5 (lane 1) or the vector alone
pSG5 (lane 2). Apoptotic rodent cells were used in lane 3 as an
ASP positive control. Lane 4 shows a fragment of hAPG5.
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more, it appears that the increase in molecular weight does
not require apoptosis. We suggest that the addition of moi-
eties such as carbohydrates may be responsible, although we
have no evidence to support this view at present. Most of the
potential modi¢cation sites shown in the legend to Fig. 2 are
not conserved in APG5 but it is not clear whether this is
signi¢cant as no protein product has yet been identi¢ed in
yeast.
In conclusion, the data presented has shown that the apop-
tosis speci¢c protein ASP is encoded by a gene present in all
mammalian species as well as in birds. The low levels of
mRNA seen in viable cells as well as in apoptotic cells indi-
cates that the high levels of protein seen are largely attribut-
able to increased translation of pre-existing mRNA. In addi-
tion the signi¢cant homology between ASP cDNA and APG5
from yeast has two important implications. Firstly it suggests
that apoptosis and autophagy are related processes or at least
employ some common mechanisms. Secondly it con¢rms the
conservation of a common biochemical pathway involved in
autophagy and apoptosis in all eukaryotes.
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